CTIM-10. PHASE II STUDY OF PEMBROLIZUMAB PLUS SurVaxM FOR GLIOBLASTOMA AT FIRST RECURRENCE

Manmeet Ahluwalia; David Peereboom; Yasmeen Rauf; Cathy Schilero; Marci Ciolfi; Michael Ciesielski; Robert Fenstermaker

doi:10.1093/NEUONC/NOAA215.144

CTIM-10. PHASE II STUDY OF PEMBROLIZUMAB PLUS SurVaxM FOR GLIOBLASTOMA AT FIRST RECURRENCE

Manmeet Ahluwalia, David Peereboom, Yasmeen Rauf, Cathy Schilero, Marci Ciolfi, Michael Ciesielski, Robert Fenstermaker

Miami Cancer Institute

Research output: Contribution to conference › Presentation

Original language	American English
DOIs	https://doi.org/10.1093/NEUONC/NOAA215.144
State	Published - Nov 9 2020
Event	Neuro-oncology - Duration: Nov 9 2020 → …

Conference

Conference	Neuro-oncology
Period	11/9/20 → …

Disciplines

Medicine and Health Sciences
Oncology
Internal Medicine

Access to Document

10.1093/NEUONC/NOAA215.144License: Unspecified

Cite this

@conference{10bdbbba715b40f087be5dad9eaaab21,

title = "CTIM-10. PHASE II STUDY OF PEMBROLIZUMAB PLUS SurVaxM FOR GLIOBLASTOMA AT FIRST RECURRENCE",

author = "Manmeet Ahluwalia and David Peereboom and Yasmeen Rauf and Cathy Schilero and Marci Ciolfi and Michael Ciesielski and Robert Fenstermaker",

note = "AbstractBACKGROUND. Pembrolizumab is a potent humanized immunoglobulin G4 monoclonal antibody with high specificity of binding to the programmed cell death 1 (P; Neuro-oncology ; Conference date: 09-11-2020",

year = "2020",

month = nov,

day = "9",

doi = "10.1093/NEUONC/NOAA215.144",

language = "American English",

}

TY - CONF

T1 - CTIM-10. PHASE II STUDY OF PEMBROLIZUMAB PLUS SurVaxM FOR GLIOBLASTOMA AT FIRST RECURRENCE

AU - Ahluwalia, Manmeet

AU - Peereboom, David

AU - Rauf, Yasmeen

AU - Schilero, Cathy

AU - Ciolfi, Marci

AU - Ciesielski, Michael

AU - Fenstermaker, Robert

N1 - AbstractBACKGROUND. Pembrolizumab is a potent humanized immunoglobulin G4 monoclonal antibody with high specificity of binding to the programmed cell death 1 (P

PY - 2020/11/9

Y1 - 2020/11/9

UR - https://academic.oup.com/neuro-oncology/article-abstract/22/Supplement_2/ii34/5960574

U2 - 10.1093/NEUONC/NOAA215.144

DO - 10.1093/NEUONC/NOAA215.144

M3 - Presentation

T2 - Neuro-oncology

Y2 - 9 November 2020

ER -

CTIM-10. PHASE II STUDY OF PEMBROLIZUMAB PLUS SurVaxM FOR GLIOBLASTOMA AT FIRST RECURRENCE

Conference

Disciplines

Access to Document

Other files and links

Cite this